A Focus on Lung Cancers

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation. (as of 3/8/2023)

Program Organizers

Kasey Bamel, DNP
University of California San Diego Moores Cancer Center

Christopher Coyne, MD, MPH
University of California San Diego Health

Misako Nagasaka, MD, PhD
University of California Irvine

Sandip P. Patel, MD
University of California San Diego Moores Cancer Center

Program Agenda

11:00–12 p.m.		In-Person Attendees: Complimentary Networking Lunch
11:55–12 p.m.		Welcome
12-12:30 p.m.		Overview of Frontline IO Options in NSCLC Sandip P. Patel, MD - University of California San Diego Moores Cancer Center
12:30–1 p.m.		Neoadjuvant and Adjuvant IO Strategies in NSCLC Misako Nagasaka, MD, PhD – University of California Irvine
1–1:30 p.m.		Managing Symptom Assessments Kasey Bamel, DNP - University of California San Diego Moores Cancer Center
1:30–2 p.m.		Assessment and Initial Intervention in the Emergency Room Christopher Coyne, MD, MPH - University of California San Diego Health
2-2:30 p.m.		Break
2:30–3:10 p.m.		Emerging Treatments, Emerging Toxicities Sandip P. Patel, MD - University of California San Diego Moores Cancer Center Christopher Coyne, MD, MPH - University of California San Diego Health
3:10–4 p.m.		Faculty Panel Kasey Bamel, DNP - University of California San Diego Moores Cancer Center Christopher Coyne, MD, MPH - University of California San Diego Health Misako Nagasaka, MD, PhD - University of California Irvine Sandip P. Patel, MD - University of California San Diego Moores Cancer Center

Program Details

Venue information

Hilton San Diego Bayfront

1 Park Blvd, San Diego, CA 92101

Rising above the San Diego Bay and steps from the Gaslamp Quarter and Petco Park, Hilton San Diego Bayfront is the signature SoCal resort. Enjoy a tailored, urban coastal experience with bright and unparalleled views in every guest room, relaxing amenities, and locally-inspired dining.

Program Learning Objectives

Summarize recent updates in cancer immunotherapy for lung cancer and toxicity management for key disease states.
Implement cancer immunotherapy for lung cancer into clinical practice appropriately.
Describe management approaches for difficult or refractory immune-related adverse events.
Describe the use of biomarkers to select appropriate cancer immunotherapies for lung cancer patients.

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

COVID-19 Measures >

At SITC programs, our goal is to have a safe and meaningful in-person experience. SITC will refer to the CDC COVID-19 Community Levels to guide health precautions for in-person meetings. In addition, SITC strongly recommends that in-person meeting attendees take the following precautions:
• Stay up to date with COVID-19 vaccinations.
• Take a rapid COVID test prior to attending a meeting and do not attend in person if you test positive.
• Do not attend the meeting if you have symptoms that could be consistent with a “cold” or any other respiratory infection and leave the meeting if you develop such symptoms.
• Wear a mask in crowded indoor settings.
• Follow all health and safety protocols as required by SITC and local and state health departments.
• Review current CDC and applicable local guidance for protecting yourself from COVID-19.
Attendees will have access to the meeting content online if they are unable to attend in person due to illness or a positive COVID test. For hybrid programs, attendees can change from in-person to online-only registration by contacting events@sitcancer.org.
Registered attendees will be notified in advance of any changes to precautions, recommendations or requirements for a SITC meeting.

Accreditation Information

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

PACE designates this continuing education activity for 3.5 contact hour(s) (0.35 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Disclosures and ADA Info

Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email education@sitcancer.org.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

Thursday, April 6, 2023 | 12-4 p.m. PDT
Hybrid | Virtual and San Diego, CA

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation. (as of 3/8/2023)

Program Organizers

Program Agenda